U.S. stock market update: Zhengye Biotechnology up 26.03%

U.S. Stock Market Midday Update Stocks with High Trading Volume in the Industry Pfizer rose 4.39%, with increased trading volume. Based on recent important news: On September 30, Trump announced a drug pricing agreement with Pfizer, causing Pfizer's stock price to rise by 2.2%. This agreement will sell drugs at lower prices through the Medicaid program, boosting market confidence. Source: The Washington Post. On September 30, Pfizer's CEO is expected to announce a $70 billion investment in drug production in the U.S., seen as a significant commitment to the U.S. market, further driving up the stock price. Source: The Wall Street Journal. On September 29, Metsera announced positive results from its GLP-1 receptor agonist research, and Pfizer has gained a broad layout in this field through the acquisition of Metsera, enhancing its competitiveness in the weight loss drug market. Source: Zhitong Finance. Increased investment in the pharmaceutical industry has boosted market confidence. Eli Lilly rose 0.78%, with increased trading volume. Based on recent key news: On September 29, Eli Lilly's potential progress in Alzheimer's treatment has attracted market attention. Leerink expects that if the relevant trial data is positive, Eli Lilly's stock price could rise to $10. On September 28, Eli Lilly announced that its oral estrogen receptor antagonist Inluriyo received FDA approval for the treatment of certain types of breast cancer patients, which boosted market confidence. On September 27, analysts generally gave Eli Lilly a "Strong Buy" rating, with a target price of $900.94, indicating a potential upside of 24.01%. The pharmaceutical industry faces pressure from tariffs and pricing policies. Johnson & Johnson rose 1.15%, with increased trading volume. Based on recent important news: On September 29, the U.S. FDA approved Johnson & Johnson's Tremfya for the treatment of pediatric psoriasis and arthritis. This approval makes Tremfya the first and only IL-23 inhibitor approved for such pediatric indications, driving up the stock price. On September 30, concerns about risks in artificial intelligence concept stocks increased, leading investors to turn to stocks with lower correlation to AI trends, with Johnson & Johnson favored for its robust performance, reaching a new high. On September 27, Johnson & Johnson's CEO expressed optimism about the future of drug innovation in the U.S. in an interview, enhancing market confidence in the company's long-term growth potential. Market concerns about AI stock risks have shifted funds towards stable stocks. Stocks with High Market Capitalization in the Industry Novartis rose 1.71%. Based on recent important news: On September 29, Novartis announced a cash offer to acquire the U.S. biopharmaceutical company Tourmaline Bio at $48 per share. This move may enhance its competitiveness in the biopharmaceutical field, driving up the stock price On September 29, Novartis plans to launch a direct-to-patient sales platform in the United States, offering a 55% discount on the Cosentyx drug. This initiative aims to improve the accessibility and affordability of the medication, potentially boosting market confidence. On September 27, Novartis announced it will invest $23 billion over the next five years to expand its facilities in the United States, which is expected to create over 1,000 jobs. This investment plan demonstrates the company's long-term commitment to the U.S. market and may have a positive impact on its stock price. Changes in pharmaceutical industry policies have significant effects